GLPwatch
Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing’s syndrome: a multicenter retrospective study.
Endocrine · 2026
Last updated 2026-05-28| Journal | Endocrine, 2026 |
|---|---|
| Citations | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity |
Full record and abstract on PubMed 41803337 ↗